Barclays analyst Steve Valiquette lowered the firm’s price target on CVS Health to $110 from $118 and keeps an Overweight rating on the shares following the Oak Street acquisition and Q4 results. The firm views the company’s 2023 outlook as mixed.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CVS:
